• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Surrogate endpoints: wishful thinking or reality?

作者信息

Baker Stuart G

出版信息

J Natl Cancer Inst. 2006 Apr 19;98(8):502-3. doi: 10.1093/jnci/djj153.

DOI:10.1093/jnci/djj153
PMID:16622112
Abstract
摘要

相似文献

1
Surrogate endpoints: wishful thinking or reality?替代终点：一厢情愿还是现实？
J Natl Cancer Inst. 2006 Apr 19;98(8):502-3. doi: 10.1093/jnci/djj153.
2
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?前列腺癌的随机II期试验及前列腺特异性抗原终点指标：小题大做？
J Clin Oncol. 2005 Nov 1;23(31):8124-5; author reply 8125-6. doi: 10.1200/JCO.2005.03.2458.
3
Efficacy vs effectiveness in prostate-specific antigen screening.前列腺特异性抗原筛查中的效能与效果
J Natl Cancer Inst. 2010 Mar 3;102(5):288-9. doi: 10.1093/jnci/djq002. Epub 2010 Feb 8.
4
Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.关于前列腺特异性抗原筛查的争议已从死亡率问题转向过度治疗问题。
Int J Urol. 2009 Sep;16(9):711-12.
5
Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?前列腺特异性抗原（PSA）速率能否作为激素难治性转移性前列腺癌试验中的替代终点？
Nat Clin Pract Urol. 2006 Jun;3(6):310-1. doi: 10.1038/ncpuro0504.
6
Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.前列腺特异性抗原（PSA）与PSA速率：在预测可治愈及具有临床意义的前列腺癌中是竞争还是协作关系。
J Clin Oncol. 2008 Feb 20;26(6):823-4. doi: 10.1200/JCO.2007.15.1902.
7
The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.前列腺癌的最大径是根治性前列腺切除标本中前列腺特异性抗原失败的一个简单、廉价的预测指标。
Cancer. 1999 Mar 1;85(5):1208-10.
8
Prostate cancer detection: beware of the low PSA.前列腺癌检测：警惕低前列腺特异性抗原水平。
Can J Urol. 2007 Jun;14(3):3534.
9
[Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial].
Prog Urol. 2009 Jul;19(7):499-500. doi: 10.1016/j.purol.2009.04.011. Epub 2009 Jun 3.
10
[Detection of prostate cancer: yes or no?].[前列腺癌的检测：是与否？]
Bull Mem Acad R Med Belg. 2006;161(3-4):159-69.

引用本文的文献

1
Predicting Clinical Outcomes Using Molecular Biomarkers.使用分子生物标志物预测临床结果
Biomark Cancer. 2016 Jun 6;8:89-99. doi: 10.4137/BIC.S33380. eCollection 2016.
2
Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone.在接受新辅助化疗加同步放化疗与单纯同步放化疗的局部晚期鼻咽癌患者中确定替代终点。
BMC Cancer. 2015 Nov 24;15:930. doi: 10.1186/s12885-015-1816-6.
3
Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial.
局部区域晚期鼻咽癌总生存的潜在替代终点：一项III期随机试验的分析
Sci Rep. 2015 Jul 29;5:12502. doi: 10.1038/srep12502.
4
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?统计考虑和临床肺癌研究的终点：无进展生存期 (PFS) 是否可以替代总生存期 (OS) 作为晚期非小细胞肺癌临床试验的有效终点？
Transl Lung Cancer Res. 2012 Mar;1(1):26-35. doi: 10.3978/j.issn.2218-6751.2011.12.08.
5
PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.在多西他赛一线治疗转移性去势抵抗性前列腺癌患者中，前列腺特异性抗原（PSA）缓解率作为总生存期中位数替代指标的研究：22项试验分析
Tumour Biol. 2014 Nov;35(11):10601-7. doi: 10.1007/s13277-014-2559-8. Epub 2014 Sep 7.
6
Postconditioning in ST-elevation myocardial infarction: a systematic review, critical appraisal, and meta-analysis of randomized clinical trials.ST段抬高型心肌梗死中的后适应：一项随机临床试验的系统评价、批判性评估和荟萃分析
Vasc Health Risk Manag. 2014 Aug 8;10:477-91. doi: 10.2147/VHRM.S67154. eCollection 2014.
7
Test the reliability of doubly robust estimation with missing response data.检验具有缺失响应数据的双重稳健估计的可靠性。
Biometrics. 2014 Jun;70(2):289-98. doi: 10.1111/biom.12150. Epub 2014 Feb 24.
8
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.无进展生存期作为胶质母细胞瘤总生存期的替代终点：基于91项试验的文献荟萃分析
Neuro Oncol. 2014 May;16(5):696-706. doi: 10.1093/neuonc/not236. Epub 2013 Dec 12.
9
CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.CYP2D6 基因型与他莫昔芬治疗乳腺癌反应：系统评价和荟萃分析。
PLoS One. 2013 Oct 2;8(10):e76648. doi: 10.1371/journal.pone.0076648. eCollection 2013.
10
A new estimation with minimum trace of asymptotic covariance matrix for incomplete longitudinal data with a surrogate process.带有替代过程的不完全纵向数据的渐近协方差矩阵最小迹新估计。
Stat Med. 2013 Nov 30;32(27):4763-80. doi: 10.1002/sim.5875. Epub 2013 Jun 7.